Advertisement
Document › Details
DVS Sciences, Inc.. (12/5/11). "Press Release: DVS Sciences Appoints Jospeh Victor as President and CEO". Sunnyvale, CA & Toronto, ON.
![]() |
Region | Sunnyvale, CA |
| Country | United States (USA) | |
![]() |
Organisation | DVS Sciences Inc. |
![]() |
Product | CyTOF® mass cytometer |
| Product 2 | MAXPAR® reagents | |
![]() |
Person | Victor, Joseph (DVS Sciences 201112– CEO before Applied Precision CEO) |
| Person 2 | Tanner, Scott (Univ Toronto 200911 + DVS Sciences 200911 CEO + co-founder) | |
DVS Sciences, Inc., a privately held innovator and manufacturer of novel CyTOF® multi-parameter single-cell analyzers and MAXPAR® reagents for biological research and potential clinical applications, today announced that Joseph Victor has been appointed President and CEO and a Director. Mr. Victor has more than 25 years of experience fostering product innovation and building value for customers, shareholders, and employees. Most recently, Mr. Victor was President and CEO of Applied Precision Inc. which was recently acquired by GE Healthcare. Before that he drove significant sales growth, new product development and overall profitability of the Applied Precision business in the roles of President, Sr. VP Life Sciences, VP R&D and Operations, and VP R&D. Prior to Applied Precision, Mr. Victor held various executive management and technical positions in the aviation, high technology, and energy markets.
Mr. Victor will assume the role of President and CEO from Dr. Scott Tanner, co-founder of DVS Sciences. "Our Board and I are delighted to welcome Joe to DVS Sciences and believe he is the ideal person to lead the company through its next phase of growth and expansion in the Life Sciences markets," said Dr. Tanner. With Mr. Victor's appointment, Dr. Tanner has transitioned to the role of Chief Technology Officer and General Manager of the company's Canadian operations providing additional focus on the research and development of the mass cytometry technology platform at DVS Sciences.
Commenting on his appointment, Mr. Victor said, "This is a truly exciting opportunity. The CyTOF mass cytometry platform clearly holds tremendous promise in enabling scientists to better understand the cellular dynamics of disease states, stem cells and other biologically relevant systems. I look forward to working with the board of directors and the DVS Sciences' team to accelerate the company's growth and success."
Mr. Victor will be located in the DVS Sciences global headquarters in Sunnyvale, California. He holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington. For more information about DVS Sciences and the CyTOF mass cytometry platform, please visit www.DVSsciences.com
About DVS Sciences, Inc.
DVS Sciences, Inc. manufactures and globally distributes novel bioanalytical solutions for use in biomarker discovery, biological research and potential future use in clinical applications. The patented multi-parameter technology comprises a high-throughput mass cytometer for quantitative individual cell analysis, CyTOF, and a suite of MAXPAR reagents, which include stable-isotope-tagged antibodies. The CyTOF - MAXPAR system overcomes the limitations of conventional flow cytometry, simplifies sample preparation and can simultaneously identify up to 100 biomarkers with high resolution and wide dynamic range. CyTOF systems are installed in leading laboratories across the U.S., Canada, Europe and Asia.
DVS Sciences has an R&D and instrument manufacturing facility near Toronto, Canada, and its global headquarters and reagent kit manufacturing is located in Sunnyvale, California.
CONTACT:
Joseph Victor
President and CEO
DVS Sciences, Inc.
639 N. Pastoria Ave.
Sunnyvale, CA 94085
Tel: +1 408-900-7214
Email: joe.victor@DVSsciences.com
Record changed: 2011-12-12 |
More documents for DVS Sciences Inc.
- [1] [iito] Business Intelligence. (1/13/12). "[MSC] Newsletter December 2011". Bremen....
- [2] DVS Sciences, Inc.. (7/14/11). "Press Release: DVS Sciences Raises $14.6 Million in Series A Financing to Advance Commercialization of Novel Single-cell Analysis Technology. Investors include 5AM Ventures, Pfizer Venture Investments, Mohr Davidow Venture...
- [3] [iito] Business Intelligence. (6/5/11). "[MSC] Newsletter May 2011. ASMS 2011 SPECIAL". Bremen....
- [4] DVS Sciences Inc.. (5/6/11). "Press Release: Science Publication Describes Novel Biology Discovered through the Use of the CyTOF Mass Cytometer and Massively Multi-parametric Single Cell Analysis". Toronto, ON....
- [5] DVS Sciences Inc.. (3/5/10). "Press Release: We Are Proud to Inform You that DVS Sciences Inc. Is Now Represented in Asia by IAS Inc.". Toronto....
- [6] DVS Sciences Inc.. (11/17/09). "Press Release: DVS Sciences Unveils First-in-Class Mass Cytometer for Use in Understanding and Diagnosing Disease". Toronto....
To subscribe to our free, monthly [MSC] Newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
NEW: Visit our brand new forthcoming web portals Life-Sciences-Germany.com and Life-Sciences-Europe.com
» top
![[MSC] Mass-Spec-Capital.com The Mass Spectrometry Web Portal](/images/basics/msc-mass-spectrometry-portal-logo.jpg)









![Banner [iiito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)